President Donald Trump’s selection to be the next head of the FDA faces a barrage of questions this week about his views on vaping, oversight of stem-cell therapies and even “Frankenfish.”
Stephen Hahn, chief medical executive of the prestigious MD Anderson Cancer Center at the University of Texas in Houston, will go before the Senate Health, Education, Labor and Pensions Committee for his first public hearing since being nominated to become commissioner of the Food and Drug Administration. Hahn met with key members of the panels in recent weeks, including committee Chairman Lamar Alexander (R-Tenn.) and members such as Sens. Lisa Murkowski (R-Alaska)
“I gave him a forewarning: usually you’ll be hearing from members from issues like drug pricing and drug availability but know that, as I am interested in that, I’m equally as interested in seafood,” Murkowski said. “That’s seafood advisory and genetically engineered fish.”
Murkowski for years blocked genetically engineered fish, sometimes derided as “Frankenfish,” from being sold in the U.S. until the FDA finished labeling guidelines for the food. The FDA earlier this year started allowing the fish into the U.S., a move Murkowski called “short sighted” at the time.
Read full, original article:`Frankenfish,’ Stem Cells, Vaping Top Questions Facing FDA Pick